General Lung Cancer


Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer (September 14, 2015)

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously... Continue Reading

Updated Trial Results Demonstrating Benefit of Opdivo® Released at the 16th World Conference on Lung Cancer (September 10, 2015)

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial... Continue Reading

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer (July 20, 2015)

The U. S. Food and Drug Administration approved IRESSA (gefitinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)... Continue Reading

Aetna Provides Coverage for Biodesix’ VeriStrat Test (June 25, 2015)

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic... Continue Reading

New Targeted Drug Offers Promising Treatment Option in Resistant EGFR-Positive Lung Cancers (June 22, 2015)

Patients with lung cancer driven by a mutation in the EGFR gene frequently respond well to inhibitors that block the mutation’s activity. But eventually, those cancers become resistant to the inhibitor... Continue Reading

Xilonix™ Promising as Treatment for Non–Small Cell Lung Cancer (May 20, 2015)

The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC). The biotechnology company XBoitech Inc recently announced clinical trial findings for the drug.[i],[ii] Xilonix... Continue Reading

EGFR Testing in Advanced Lung Cancer Appears Underutilized (April 28, 2015)

The results of a recent survey suggest that nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) testing before starting treatment. The recent development... Continue Reading

Sutent® Maintenance Therapy Found Active in Small-Cell Lung Cancer (March 17, 2015)

Cancer Connect: Doctors have reported that maintenance therapy using Sutent® (sunitinib) delays the time to cancer progression and improves survival in patients with extensive-stage small-cell lung cancer... Continue Reading

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer (March 11, 2015)

CancerConnect News: The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung... Continue Reading

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer (February 26, 2015)

CancerConnect News: The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (February 11, 2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding... Continue Reading

References (February 10, 2015)

1 Chemotherapy for non small cell lung cancer: http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/chemotherapy-stage-iv-non-small-cell-lung-cancer 2 Second Phase... Continue Reading

References for Non Small Cell Lung Cancer (February 10, 2015)

1 Chemotherapy for non small cell lung cancer: http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/chemotherapy-stage-IIIB-non-small-cell-lung-cancer 2 Second... Continue Reading

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC (February 10, 2015)

In a phase II trial reported in the Journal of Clinical Oncology doctors reported that the addition of linifanib to carboplatin-paclitaxel chemotherapy the outcomes in patients with advanced nonsquamous... Continue Reading

References (February 6, 2015)

1 The International Adjuvant Lung Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected Non-Small Cell Lung Cancer. New England Journal of Medicine. 2004;350:351-360. 2... Continue Reading

Radiation Therapy (February 6, 2015)

Some patients with NSCLC are not able to undergo the surgery to remove their cancer. Advanced age and other medical conditions such as heart disease and diminished lung capacity make it more difficult... Continue Reading

« Previous PageNext Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS